NCT01088880已完成2 期
An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- To measure the effect of canakinumab on the frequency of FMF attacks defined as percentage of patients with at least 50% reduction in the attack frequency during 3 month treatment period.
研究概览
简要总结
Establish the safety and efficacy of 3 months treatment with canakinumab in patients with colchicine resistant Familial Mediterranean Fever.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients between 12 and 75 years of age with active type 1 FMF disease (according to Tel-Hashomer criteria for diagnosis of FMF) despite colchicine therapy (1.5 to 2.0 mg/day).
- •Patients who are intolerant to effective doses of colchicine (1.5 to 2 mg/day)
- •Patients with demonstrated minimum 1 typical acute attack per month and genetic confirmation of diagnosis (with at least one of the known MEFV gene exon 10 mutations). Patients with manifested amyloidosis are excluded.
- •Patients must have a historical data showing a frequency of at least 1 attack/month within the last 3 months before they can be enter the run-in period.
- •Patients must have type 1 disease characterized by recurrent and short episodes of inflammation and serositis with an average of at least 1 documented acute FMF attack per month during the previous 6 months and lasting approximately 12 to 72 hours.
- •Patients treated with IL-1 therapies must complete washout and have experienced at least 2 attacks since (e.g. Anakinra: 3 day washout; Rilonacept: 3 week washout)
- •Patients treated with anti-TNF drugs must undergo appropriate washout. Prior to randomization, use of Etanercept must be discontinued for 4 weeks or use of Adalimumab or Infliximab must be discontinued for 8 weeks.
- •Female subjects of childbearing potential must be using two acceptable methods of contraception
- •Patients treated with Interferon therapies must complete 1 month washout period.
排除标准
- •Patients with end-organ dysfunction due to amyloidosis (e.g. existing biopsy proven amyloidosis or proteinuria > 0.5 gram per day)
- •Patients taking steroids within 1 month prior to baseline
- •Presence or history of any other inflammatory rheumatic disease
- •Positive PPD test (according to local guidance) where a latent or active TB infection cannot be excluded via Quantiferon (T-Spot or radiographic imaging if needed).
- •Patients who are pregnant or lactating
- •Presence of any active or chronic infection or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 30 days or oral antibiotics within 14 days prior to screening
- •History or a malignancy within the last 5 years, except for successfully excised squamous or basal cell carcinoma of the skin
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
Canakinumab
Experimental
干预措施: Canakinumab (Drug)
结局指标
主要结局
To measure the effect of canakinumab on the frequency of FMF attacks defined as percentage of patients with at least 50% reduction in the attack frequency during 3 month treatment period.
时间窗: 12 weeks
次要结局
- To assess the effect of canakinumab with regard to percentage of patients with no attacks in month 3.(12 weeks)
- To find the optimal dose of canakinumab for FMF in this population(12 weeks)
- To assess changes in the severity (acute phase response and VAS evaluation of attack severity by patient) and duration of acute attacks during the treatment period(12 weeks)
- To assess PK/PD properties of canakinumab by measuring canakinumab and IL-1beta levels before dosing
- To evaluate the safety and tolerability of canakinumab by monitoring adverse events and patient discontinuations due to AE
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDAdult Onset Still's DiseaseNCT04717635Novartis Pharmaceuticals14
已完成
3 期
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIASystemic Juvenile Idiopathic ArthritisNCT02396212Novartis Pharmaceuticals19
已完成
2 期
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular InvolvementBehcet DiseaseNCT02756650Novartis Pharmaceuticals8
终止
3 期
Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory DiseaseNOMIDCINCA SyndromeNCT00770601Novartis Pharmaceuticals7
终止
3 期
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)Systemic Juvenile Idiopathic ArthritisNCT00886769Novartis Pharmaceuticals84